(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-8.50% $ 9.15
Live Chart Being Loaded With Signals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases...
Stats | |
---|---|
Объем за сегодня | 280.00 |
Средний объем | 1 492.00 |
Рыночная капитализация | 1.99M |
EPS | $0 ( 2023-09-29 ) |
Last Dividend | $0.150 ( 2024-01-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.47 |
ATR14 | $0.358 (3.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Common Stock |
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Warrants (right to buy) |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Common Stock |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Warrants (right to buy) |
2023-06-30 | Rombotis Spiro George | Buy | 110 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 4 220 559 | Sell: 12 |
Cyclacel Pharmaceuticals Корреляция
10 Самые положительные корреляции | |
---|---|
ALSA | 0.919 |
LCAA | 0.913 |
XFIN | 0.908 |
ALXN | 0.905 |
IQ | 0.905 |
PLYA | 0.904 |
JUGG | 0.902 |
IVCP | 0.901 |
VPCB | 0.901 |
TIOAU | 0.9 |
10 Самые отрицательные корреляции | |
---|---|
SIDU | -0.91 |
MTP | -0.902 |
JAGX | -0.902 |
EVLO | -0.892 |
ENNV | -0.89 |
PROC | -0.889 |
DBGI | -0.885 |
LGMK | -0.885 |
TRMK | -0.883 |
SLNG | -0.879 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Cyclacel Pharmaceuticals Финансовые показатели
Annual | 2023 |
Выручка: | $420 000 |
Валовая прибыль: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2023 |
Выручка: | $420 000 |
Валовая прибыль: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2022 |
Выручка: | $0 |
Валовая прибыль: | $-32 000.00 (0.00 %) |
EPS: | $-32.23 |
FY | 2021 |
Выручка: | $0.00 |
Валовая прибыль: | $0.00 (0.00 %) |
EPS: | $-9.93 |
Financial Reports:
No articles found.
Cyclacel Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.150 | 2006-01-18 |
Last Dividend | $0.150 | 2024-01-19 |
Next Dividend | $0 | N/A |
Payout Date | 2024-02-01 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $8.85 | -- |
Avg. Dividend % Per Year | 5.36% | -- |
Score | 4.44 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 0.683 | -- |
Year | Amount | Yield |
---|---|---|
2006 | $0.600 | 14.50% |
2007 | $0.600 | 11.20% |
2008 | $0.600 | 12.60% |
2009 | $0.150 | 7.89% |
2010 | $0 | 0.00% |
2011 | $0.300 | 7.71% |
2012 | $0 | 0.00% |
2013 | $0.600 | 6.67% |
2014 | $0.750 | 8.13% |
2015 | $0.450 | 6.96% |
2016 | $0.600 | 15.30% |
2017 | $0.600 | 9.68% |
2018 | $0.600 | 9.16% |
2019 | $0.600 | 9.60% |
2020 | $0.450 | 9.00% |
2021 | $0.600 | 8.53% |
2022 | $0.600 | 9.68% |
2023 | $0.600 | 5.19% |
2024 | $0.150 | 0.91% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -53.86 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -2.57 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.10 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.00889 | -1.000 | -0.0889 | 0.0889 | [0 - 1] |
currentRatioTTM | 0.912 | 0.800 | -0.439 | -0.351 | [1 - 3] |
quickRatioTTM | 0.773 | 0.800 | -0.157 | -0.126 | [0.8 - 2.5] |
cashRatioTTM | 0.414 | 1.500 | 8.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00420 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 239.38 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -9.44 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0610 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0580 | 1.000 | -2.37 | -2.37 | [0.2 - 0.8] |
operatingProfitMarginTTM | -61.55 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -435.46 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0477 | 0.800 | -3.02 | -2.41 | [0.5 - 2] |
Total Score | -3.63 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0570 | 1.000 | -0.107 | 0 | [1 - 100] |
returnOnEquityTTM | -3.10 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.00889 | 1.500 | -0.0889 | 0.0889 | [0 - 1] |
pegRatioTTM | -0.00201 | 1.500 | -3.35 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -38.36 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -4.53 |
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа